秒速时时彩

You are here: Home> Investor Relations> Announcement
  • 26

    2020-02

    The Group's "Montelukast Sodium Tablets and Chewable Tablets" was approved for drug registration

  • twenty four

    2020-02

    CSPC Xinnuowei Pharmaceutical Co., Ltd. Annual Results Flash for the year ended 31 December 2019

  • twenty four

    2020-02

    New drug under investigation ALMB-0168 approved for clinical trials in Australia

  • 04

    2020-02

    Monthly Return Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2020

    Monthly Return of Equity Issuer on Movements in Securities for the Month Ended January 31, 2020 ...

  • twenty two

    2020-01

    CSPC Xinnuowei Pharmaceutical Co., Ltd. Annual Results Forecast for the Year Ended December 31, 2019

  • 20

    2020-01

    Results of the National Drug Centralized Procurement Plan

  • 02

    2020-01

    The Group's Sunitinib Malate Capsule was approved for drug registration

    Sunitinib Malate Capsules ...

  • 02

    2020-01

    The Group's "Pramexol Hydrochloride" was approved for drug registration

    CSPC Group Praxox Hydrochloride Obtained Drug Registration Approval ...

  • 31

    2019-12

    The Group's Pregabalin Capsules Approved for New American Simple Drugs

    CSPC's Pregabalin Capsule Application for U.S. Minimal New Drug Approved ...

  • 31

    2019-12

    Voluntary Announcement-Termination of Product Cooperative Development and Strategic Cooperation Agreement

    Voluntary announcement to terminate product cooperation development and strategic cooperation agreement ...

  • 20

    2019-12

    CSPC's L-Amlodipine maleate is approved by the FDA

    CSPC's L-Amlodipine maleate has been approved by the US FDA for new drugs ...

  • 11

    2019-12

    CSPC `` ibuprofen tablets '' pass consistency evaluation

  • 02

    2019-12

    Monthly Return Monthly Return of Equity Issuer on Movements in Securities for the Month Ended November 30, 2019

  • 02

    2019-12

    [Continuing Connected Transactions] Revise the annual caps of existing continuing connected transactions

  • 27

    2019-11

    CSPC submits clinical trial application for the first innovative drug of its kind in Australia, ALMB-0168, in Australia